Nabi Biopharmaceuticals (NASDAQ:NABI) and Biota Holdings have signed a Merger Implementation Agreement to form a combined company Biota Pharmaceuticals, which will be listed on NASDAQ and headquartered in the United States. Nabi will buy all of the shares in Biota, and replace them with new Biota Pharmaceuticals shares. Biota will be de-listed from the ASX. After closing the transaction, current Biota shareholders will own about 74 percent of the new company, and Nabi shareholders with approximately 26 percent. Nabi plans to return cash in excess of the $54 million required to be held by Nabi at closing to its current investors, after satisfying certain obligations. Better value recognition of Biota is the goal desired from the move, to be accomplished through a stronger base of shareholders. The consolidated firm will possess products Relenza, Inavir and potentially PhosLyra, all of which will generate royalties; a portfolio of clinical and pre-clinical programs comprising vapendavir, and programs for respiratory syncytial virus, hepatitis C, or HCV-NN, broad spectrum antibiotic targeting gyrase, or GYR; A contract with BARDA worth $231 million for the advanced development of laninamivir; an interest in NicVAX, and more than $100 million in cash.
Wal-Mart Stores Inc. (NYSE:WMT) could have legal troubles, according to the Wall Street Journal, as it looks into its operations in Mexico. Some experts in the field say that a U.S. law that disallows bribery in foreign countries, might have been violated.
Toyota (NYSE:TM), Honda (NYSE:HMC) and Nissan (NSANY) are expected to ‘race ahead’, according to the Wall Street Journal, after last year’s natural disasters, currency rate difficulties, and their disappointing lineups.
ABB’s (NYSE:ABB) CEO Hogan quashes rumors that the company might make an offer for Rockwell (NYSE:ROK), according to Handelsblatt (Reuters), but ABB is mulling the closing of gaps in their automation and transmission portfolio with acquisitions.
Barnes & Noble (NYSE:BKS) shares pop 20% on news of hedge fund Jana Partners boosting its stake in the company to roughly 12%.
L’Oreal (LRLCY) might be planning to acquire soap and baby products company Cadum in a transaction that could total $264.16 million, says Les Echos (Reuters).
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.